礼来公司的Jaypirca获得了治疗未经治疗的白血病、淋巴瘤的额外适应症

2026-10-03 04:20

The US FDA granted an additional indication for Eli Lilly's (LLY) Jaypirca (pirtobrutinib) as a first-line treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
The non-covalent BTK inhibitor was approved in this indication based on results from the BRUIN CLL-313 study, which compared Jaypirca to a combination of bendamustine plus rituximab.
Results showed that progression-free survival was significantly better in the Jaypirca cohort, and the overall response rate in that group was 94%.
Another ongoing phase 3 study, BRUIN CLL-314, is comparing Jaypirca to Johnson & Johnson's (JNJ)/AbbVie's (ABBV) Imbruvica (ibrutinib) in BTK inhibitor-naive individuals with CLL/SLL.

More on Eli Lilly